NeuroSense Announces First Quarter 2024 Business Update
Corporate Highlights from Q1 2024 and To Date
- Merit Cudkowicz, M.D.,
M.Sc ., chair of neurology and Director of the Sean M. Healey &AMG Center for ALS atMassachusetts General Hospital presented full data update from PARADIGM in ALS during Emerging Sciences (late-breaker equivalent) presentation at theAmerican Academy of Neurology annual meeting - Announced collaboration with Genetika+ to apply their precision medicine methodology to better quantify neuronal plasticity as part of the Company's ongoing Phase 2 Alzheimer's disease trial
- Entered into collaboration with Lonza (SIX: LONN) to identify exosome-based biomarkers to further advance PrimeC in ALS
- Company announced subsequent analyses of quality of life and complication free survival from the PARADIGM Study, which demonstrated positive results as well as positive trends of key biomarker outcome of neurofilament light chain (NfL) levels
"The first several months of 2024 have proven to be very productive for NeuroSense as we have entered into multiple key collaborations that we expect will help to enhance the development of PrimeC both for ALS and Alzheimer's disease. In addition, our PARADIGM results received significant validation when they were accepted as late breaking data at the AAN conference," stated NeuroSense CEO
"As we proceed through the second quarter, we anticipate further collaborations as well as to schedule an end of Phase 2 study with FDA in order to continue this important research into a Phase 3 clinical trial. We look forward to providing additional new data from the PARADIGM trial," concluded Mr. Ben-Noon.
About ALS
Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 patients are diagnosed with ALS in the
About PrimeC
PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS. NeuroSense completed the 6-month double blind portion of PARADIGM, a prospective, multinational, randomized, double-blind, placebo-controlled Phase 2b ALS (NCT05357950) clinical trial, which met its safety and tolerability endpoints, as well as showing a statistically significant slowing of disease progression in the pre-specified Per Protocol (PP) population. PrimeC was granted Orphan Drug Designation by the
About NeuroSense
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on
Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/neurosense-announces-first-quarter-2024-business-update-302134572.html
SOURCE NeuroSense